AIM
NBSE

Acrospire Investment Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Acrospire Investment Management’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1
Closed – – 2609
2017
Q1 		$0 Sell
1
-27
-96% -$12.5K ﹤0.01% 2562
2016
Q4 		$17K Buy
28
+12
+75% +$12.7K 0.01% 1825
2016
Q3 		$18K Sell
16
-20
-56% -$21.6K 0.01% 1540
2016
Q2 		$39K Buy
+36
New +$45.2K 0.03% 1242

Other funds holding NBSE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $92.2M AUM 19.08% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 19.31% 1-Year Est. Return

Acrospire Investment Management's NBSE Position: Q2 2017 in Review

Acrospire Investment Management sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2017, closing a stake of 1 share.

Acrospire Investment Management first reported a position in NBSE in Q2 2016 and held it in 4 quarters. The position peaked at $39K in Q2 2016. 38 funds tracked by Wall St. Rank hold NBSE as of Q2 2017.

  • Acrospire Investment Management reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 1 NeuBase Therapeutics, Inc. Common Stock share in Q2 2017.
  • Acrospire Investment Management first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2016 and held it in 4 quarters.
  • Acrospire Investment Management's NeuBase Therapeutics, Inc. Common Stock position peaked at $39K in Q2 2016.
  • 38 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.